HK Stock Market Move | CHINA WANTIAN (01854) rose over 6%. The loss in the first half of the year narrowed by 37.96% year-on-year. The company will adopt a "dual-engine" growth strategy.
China Wantian Holdings (01854) rose by over 6%. As of the time of publication, it is up 6.02%, priced at HKD 1.145, with a trading volume of HKD 5.7727 million.
CHINA WANTIAN (01854) surged more than 6%, and as of the time of writing, it rose by 6.02% to HK$1.145, with a trading volume of HK$5.7727 million.
On the news front, CHINA WANTIAN recently released its interim results for the six months ending June 30, 2026, revealing that the group achieved revenue of HK$377 million, a year-on-year decrease of 38.76%; the loss attributable to shareholders was HK$29.01 million, a year-on-year decrease of 37.96%; with a loss per share of HK$0.0142. Looking ahead to the second half of 2026 and beyond, the group will adopt a "dual-engine" growth strategy, systematically integrating its solid operational foundation with cutting-edge artificial intelligence, business Siasun Robot & Automation, and smart hardware solutions.
The announcement stated that the group has established a flexible light-asset framework through recent property restructuring and lease optimization, thereby laying a superior strategic advantage, expected to create new high-margin revenue sources in the Guangdong-Hong Kong-Macao Greater Bay Area while upgrading its core business channels. The group's technology platform operates not in isolation but is underpinned by Shenzhen Wantian Artificial Intelligence Technology, serving as an operational catalyst directly integrated into daily business workflows, enterprise customer service, and supply chain management.
Related Articles

How to choose AI applications in Hong Kong stocks? DIAGENS-B (02526): A rare vertical AI target with high growth and strong barriers.

Valuation at $2 trillion! Anthropic may become the largest IPO in history, starting its roadshow in October and going public before the mid-term elections in November.

Astrazeneca PLC Sponsored ADR (AZN.US) has received accelerated approval from the FDA for a new breast cancer drug, and Wall Street estimates that sales could reach $2.3 billion by 2032.
How to choose AI applications in Hong Kong stocks? DIAGENS-B (02526): A rare vertical AI target with high growth and strong barriers.

Valuation at $2 trillion! Anthropic may become the largest IPO in history, starting its roadshow in October and going public before the mid-term elections in November.

Astrazeneca PLC Sponsored ADR (AZN.US) has received accelerated approval from the FDA for a new breast cancer drug, and Wall Street estimates that sales could reach $2.3 billion by 2032.

RECOMMEND





